Relmada Therapeutics Inc. (RLMD)
NASDAQ: RLMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RLMD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $279.54M
- EPS (TTM)
- -$0.73
- Dividend yield
- None
- 52-week range
- 2.60 – 8.00
- Day range
- 2.60 – 3.13
- Volume / Avg
- 2.25M / 1.45M
- Beta
- —
- Shares outstanding
- 106.69M
52-week range
RLMD stock today
Relmada Therapeutics (RLMD) closed at $2.62 on Nov 20, down 15.76% (-$0.49), versus the S&P 500's 3.70% decline. Shares are 67.3% below their 52-week high of $8.00, set on May 6, 2026 and 0.7% above the 52-week low of $2.60, near the bottom of the past year's range. RLMD is down 45.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.6%.
Relmada Therapeutics has posted a net loss over the last twelve months (EPS of -$0.73), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Relmada Therapeutics
Company profileRelmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Sergio Traversa M.B.A., Pharm.D.
- Headquarters
- Coral Gables, FL
- Employees
- 17
- Website
- relmada.com
Financial highlights
Full financialsRelmada Therapeutics reported a net loss of $57.4 million, compared with a loss of $80.0 million a year earlier. Diluted earnings per share came in at -$1.45.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-57.39M | $-79.98M | $-98.79M | $-157.04M | $-125.75M |
| EPS (diluted) | $-1.45 | $-2.65 | $-3.28 | $-5.30 | $-7.16 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$10.75+310.31%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.12 vs $-0.14
- Surprise
- +14.29%
RLMD news
All RLMD news- Relmada Therapeutics, Inc. Appoints Jørn Skibsted Jakobsen, MD, PhD, as Chief Development OfficerNasdaq
- Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development OfficerGlobeNewswire
- Relmada (RLMD) Q3 2026 Earnings Call TranscriptNasdaq
- Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026GlobeNewswire
Relmada Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FULCFulcrum Therapeutics Inc. | 3.69 | -0.54% | $281.85M | vs RLMD |
| GLSIGreenwich LifeSciences Inc. | 19.25 | -2.73% | $282.56M | vs RLMD |
| BNTCBenitec Biopharma Inc. | 7.92 | -2.76% | $285.88M | vs RLMD |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs RLMD |
| EVMNEvommune Inc. | 7.04 | -2.76% | $291.10M | vs RLMD |
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs RLMD |
| SPRYARS Pharmaceuticals Inc. | 2.96 | -11.90% | $297.56M | vs RLMD |
| EBSEmergent BioSolutions Inc. | 5.05 | -1.94% | $259.65M | vs RLMD |
Indexes, lists and sector
Relmada Therapeutics stock FAQ
What is Relmada Therapeutics's stock price today?
RLMD last traded at $2.62 as of Nov 20, 4:00 PM EST, down 15.76% on the day. Prices are delayed at least 15 minutes.
Does Relmada Therapeutics pay a dividend?
No. Relmada Therapeutics does not currently pay a regular cash dividend.
Who is Relmada Therapeutics's CEO?
Dr. Sergio Traversa M.B.A., Pharm.D. is the chief executive officer of Relmada Therapeutics Inc., which has about 17 employees.
Has RLMD ever split its stock?
Yes. The most recent RLMD stock split was a 1-for-4 split on Sep 30, 2019, one of 2 splits on record.
What is the RLMD 52-week high?
The 52-week high for RLMD is $8.00 and the 52-week low is $2.60. The stock is currently 67.3% below its high.